author-photo

Kazushi Araki

Daiichi Sankyo

36

Papers

319

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930

2019 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (1)
First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) – Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (6)
Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia

2018 Leukemia
Show All
- Source
- Cite
- Save
Citations (50)
Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization

2018 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (6)
First-in-Human Study of the EZH1/2 Dual Inhibitor DS-3201b in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas — Preliminary Results

2017 Blood
Show All
- Source
- Cite
- Save
Citations (23)
Abstract 4672: Novel epigenetic approach to relapsed mantle cell lymphoma based on dual inhibition of EZH1/EZH2

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
EZH1/2, SWI/SNF, and MLL2 Dependent Heterochromatin Formation and Abnormal Transcriptome in Hematological Malignancies

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Development and Molecular Analysis of Synthetic Lethality By Targeting EZH1 and EZH2 in Non-Hodgkin Lymphomas

2016 Blood
Show All
- Source
- Cite
- Save
Citations (13)
Abstract 913: Novel leukemia stem cell-targeted therapy for acute myeloid leukemia based on dual inhibition of EZH1/EZH2

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)